Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Sales (2021 - 2024)

Allogene Therapeutics' Return on Sales history spans 4 years, with the latest figure at 11510.32% for Q4 2024.

  • For Q4 2024, Return on Sales fell 775584.0% year-over-year to 11510.32%; the TTM value through Dec 2024 reached 11510.32%, down 879268.0%, while the annual FY2024 figure was 11708.64%, 826374.0% down from the prior year.
  • Return on Sales for Q4 2024 was 11510.32% at Allogene Therapeutics, down from 6384.35% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.03% in Q4 2021 and bottomed at 24115.25% in Q4 2022.
  • The 4-year median for Return on Sales is 2965.18% (2024), against an average of 4325.23%.
  • The largest annual shift saw Return on Sales crashed -2411528bps in 2022 before it skyrocketed 2036077bps in 2023.
  • A 4-year view of Return on Sales shows it stood at 0.03% in 2021, then tumbled by -96373200bps to 24115.25% in 2022, then skyrocketed by 84bps to 3754.48% in 2023, then tumbled by -207bps to 11510.32% in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Return on Sales are 11510.32% (Q4 2024), 6384.35% (Q3 2024), and 3094.51% (Q2 2024).